As the number of infections from severe acute respiratory syndrome coronavirus 2 (“SARS‑CoV‑2”), the virus that causes COVID-19, continues to rise globally, interest in effective treatment options remains a concerted focus internationally. One potential treatment option that holds promise is the use of convalescent plasma. The FDA’s recently released “Investigational COVID-19 Convalescent Plasma, Guidance... READ MORE
FDA Details Authorized Treatment Pathways and Collection Requirements for Administration of COVID-19 Convalescent Plasma
Posted on April 21, 2020 in Health Law News
Published by: Hall Render
